Literature DB >> 3891281

Cisplatin nephrotoxicity: a summary of preventative interventions.

R S Finley, C L Fortner, W R Grove.   

Abstract

Nephrotoxicity is usually the dose-limiting toxicity associated with cisplatin therapy. Frequently the nephrotoxicity is mild and reversible. However, it is both dose-related and cumulative and may become life-threatening and irreversible at higher dosages. Many interventions such as vigorous hydration, osmotic or loop diuretics, and alterations of infusion times have been evaluated in the hope of ameliorating this serious toxicity, and are summarized. More recently, hypertonic NaCl 0.9% has been reported to decrease the incidence of cisplatin nephrotoxicity. In addition, newer platinum analogs are currently undergoing clinical trials to ascertain if they retain the antitumor properties of cisplatin but produce less toxicity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891281     DOI: 10.1177/106002808501900505

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  10 in total

1.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.

Authors:  Emiko Sakaida; Shunichiro Iwasawa; Ryota Kurimoto; Takahiro Ebata; Chiaki Imai; Tomoko Oku; Ikuo Sekine; Yuji Tada; Koichiro Tatsumi; Yuichi Takiguchi
Journal:  Jpn J Clin Oncol       Date:  2016-01-10       Impact factor: 3.019

3.  Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients.

Authors:  Hyung Hwan Moon; Kyung Won Seo; Ki Young Yoon; Yeon Myung Shin; Kyung Hyun Choi; Sang Ho Lee
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

4.  Measurement of glomerular function during cisplatin therapy.

Authors:  D G Waller; L Juer; J S Fleming
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 5.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

6.  Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis.

Authors:  Takanori Miyoshi; Toshinobu Hayashi; Miyuki Uoi; Fuyuki Omura; Kyouichi Tsumagari; Sachi Maesaki; Chiaki Yokota; Takafumi Nakano; Takashi Egawa
Journal:  Support Care Cancer       Date:  2022-01-05       Impact factor: 3.603

7.  Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Authors:  P A Steerenberg; G Storm; G de Groot; A Claessen; J J Bergers; M A Franken; Q G van Hoesel; K L Wubs; W H de Jong
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.

Authors:  C de Gislain; M Dumas; P d'Athis; J L Lautissier; A Escousse; J Guerrin
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.

Authors:  S C White; P Lorigan; G P Margison; J M Margison; F Martin; N Thatcher; H Anderson; M Ranson
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

10.  Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose Cisplatin.

Authors:  Akira Ouchi; Masahiko Asano; Keiya Aono; Tetsuya Watanabe; Takehiro Kato
Journal:  J Oncol       Date:  2014-09-24       Impact factor: 4.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.